title: Acetyl-L-carnitine in neuropathic pain: experimental data.
abstract: Acetyl-L-carnitine (ALC) has gained clinical interest for its analgesic effect in different forms of neuropathies associated with chronic pain, such as diabetic and HIV-related peripheral neuropathies. The antinociceptive effect of ALC has been confirmed in several experimental models of neuropathic pain, including streptozotocin- and chemotherapy-induced neuropathy, and the sciatic nerve chronic constriction injury model. In these models, prophylactic administration of ALC has proven to be effective in preventing the development of neuropathic pain. In addition, ALC is known to produce a strong antinociceptive effect when given after neuropathic pain has been established. ALC can also improve the function of peripheral nerves by increasing nerve conduction velocity, reducing sensory neuronal loss, and promoting nerve regeneration. Analgesia requires repeated administrations of ALC, suggesting that the drug regulates neuroplasticity across the pain neuraxis. Recent evidence indicates that ALC regulates processes that go beyond its classical role in energy metabolism. These processes involve the activation of muscarinic cholinergic receptors in the forebrain, and an increased expression of type-2 metabotropic glutamate (mGlu2) receptors in dorsal root ganglia neurons. Induction of mGlu2 receptors is mediated by acetylation mechanisms that involve transcription factors of the nuclear factor (NF)-kappaB family.
authors: Department of Pharmaceutical Sciences, University of Catania, Catania, Italy.
authors: Santina
authors: S
authors: Chiechio
authors: Agata
authors: A
authors: Copani
authors: Robert W
authors: RW
authors: Gereau
authors: Ferdinando
authors: F
authors: Nicoletti
mesh_terms: D000108:Acetylcarnitine / Q000627:therapeutic use*; D000698:Analgesia; D000818:Animals; D006801:Humans; D018697:Nootropic Agents / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D018094:Receptors, Metabotropic Glutamate / Q000235:genetics / Q000378:metabolism; D011976:Receptors, Muscarinic / Q000187:drug effects; D010738:Type C Phospholipases / Q000378:metabolism
chemical_list: D018697:Nootropic Agents; D018094:Receptors, Metabotropic Glutamate; D011976:Receptors, Muscarinic; C108822:metabotropic glutamate receptor 2; D000108:Acetylcarnitine; D010738:Type C Phospholipases
references: Farmaco. 2001 May-Jul;56(5-7):383-5
references: 11482763
references: Brain Res Dev Brain Res. 1999 Jan 11;112(1):39-53
references: 9974158
references: J Neurophysiol. 2006 Oct;96(4):1803-15
references: 16760343
references: Neurosci Lett. 2000 Jun 30;287(3):236-8
references: 10863038
references: Science. 2000 Jun 9;288(5472):1765-9
references: 10846153
references: Life Sci. 1996;58(12):991-1000
references: 8786711
references: J Neurosci Res. 1988 Aug;20(4):491-6
references: 2846861
references: Diabetologia. 1995 Jan;38(1):123
references: 7744218
references: Mol Pain. 2006 Jun 09;2:20
references: 16764720
references: Drug Saf. 1998 Dec;19(6):481-94
references: 9880091
references: Tumori. 2005 Mar-Apr;91(2):135-8
references: 15948540
references: J Biol Chem. 2002 Feb 15;277(7):4973-80
references: 11739381
references: Neuropsychopharmacology. 2003 May;28(5):888-97
references: 12736633
references: Br J Pharmacol. 2002 Mar;135(5):1255-62
references: 11877334
references: Metabolism. 1995 May;44(5):677-80
references: 7752919
references: Mol Pharmacol. 2002 May;61(5):989-96
references: 11961116
references: Neuropharmacology. 2002 Dec;43(7):1180-7
references: 12504925
references: AIDS. 2004 Jul 23;18(11):1549-60
references: 15238773
references: Cell. 2003 Jan 10;112(1):113-22
references: 12526798
references: Biochim Biophys Acta. 1986 Mar 21;876(1):175-7
references: 3081044
references: J Physiol. 2002 Sep 15;543(Pt 3):807-18
references: 12231640
references: Diabetes Care. 2005 Jan;28(1):89-94
references: 15616239
references: Neuroscience. 2000;100(2):393-406
references: 11008177
references: Drugs R D. 2002;3(4):223-31
references: 12455197
references: J Pharmacol Exp Ther. 1998 Dec;287(3):897-902
references: 9864270
references: Br J Pharmacol. 2000 Apr;129(8):1633-40
references: 10780968
references: Pain. 2004 Jan;107(1-2):22-32
references: 14715385
references: J Neurochem. 2001 Dec;79(5):959-69
references: 11739607
references: In Vivo. 2005 May-Jun;19(3):631-7
references: 15875786
references: J Neurosci. 2002 Aug 1;22(15):6388-93
references: 12151517
references: Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):283-96
references: 12769620
references: Br J Pharmacol. 1992 Jan;105(1):77-82
references: 1375858
references: Physiol Rev. 1983 Oct;63(4):1420-80
references: 6361812
references: Clin Ther. 2000 Aug;22(8):911-36; discussion 898
references: 10972629
references: J Comp Neurol. 1999 Aug 9;410(4):627-42
references: 10398053
references: Pharmacol Biochem Behav. 2002 Sep;73(2):419-27
references: 12117597
references: Clin Cancer Res. 2003 Nov 15;9(15):5756-67
references: 14654561
references: J Clin Invest. 1996 Apr 15;97(8):1900-7
references: 8621774
references: Support Care Cancer. 2004 Sep;12(9):619-25
references: 15258838
references: Pain. 2003 Dec;106(3):411-7
references: 14659524
references: Neuroreport. 1997 Aug 18;8(12):2695-9
references: 9295103
references: Biopharm Drug Dispos. 2003 Nov;24(8):357-65
references: 14595704
references: EMBO Rep. 2003 Oct;4(10):944-7
references: 14528264
references: Neurosci Lett. 2002 Dec 16;334(3):181-5
references: 12453625
references: J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jun 1;9(2):153-61
references: 7749792
references: Anesth Analg. 1997 Oct;85(4):847-53
references: 9322468
references: Trends Pharmacol Sci. 2001 Mar;22(3):114-20
references: 11239574
references: AIDS. 1997 Feb;11(2):185-90
references: 9030365
references: Pain. 1988 Apr;33(1):87-107
references: 2837713
references: Science. 2001 Aug 31;293(5535):1653-7
references: 11533489
references: Pharmacol Biochem Behav. 2002 Sep;73(2):429-37
references: 12117598
references: Anticancer Res. 2005 Jul-Aug;25(4):2681-7
references: 16080512
references: J Endocrinol Invest. 2004;27(6 Suppl):171-6
references: 15481819
references: J Neurophysiol. 2007 Jan;97(1):102-9
references: 17050831
references: Neurosci Lett. 2006 Apr 24;397(3):219-23
references: 16406309
references: Semin Cell Dev Biol. 2006 Oct;17(5):592-604
references: 17110139
references: J Pharmacol Exp Ther. 1993 Jul;266(1):329-38
references: 8101218
references: Nat Neurosci. 2003 Feb;6(2):161-7
references: 12514737
references: Clin Neurol Neurosurg. 2005 Apr;107(3):181-6
references: 15823672
references: Neuropharmacology. 2004 Aug;47(2):286-94
references: 15223307
references: J Peripher Nerv Syst. 1997;2(3):250-2
references: 10975731
references: J Neurochem. 1981 Apr;36(4):1323-30
references: 6790669
references: Pain. 2006 Jun;122(3):245-57
references: 16530964
references: Curr Neuropharmacol. 2006 Jul;4(3):233-7
references: 18615142
references: AIDS. 2000 Feb 18;14(3):273-8
references: 10716503
references: IUBMB Life. 2005 Mar;57(3):137-49
references: 16036576
references: Neuropharmacology. 2005;49 Suppl 1:206-18
references: 15998527